People in brief | Strides, Carlyle, GlaxoSmithKline
9 January 2020
Strides Pharma Science has a new chief, The Carlyle Group has taken on Ian Read, and GlaxoSmithKline has a new member of its Corporate Executive Team.
Industry News - Tag: GlaxoSmithKline
You can read Premium News stories in full if you have an Annual Subscription to the OTCToolbox website. You can read Basic News stories free of charge.
GlaxoSmithKline gets a lift from Pfizer portfolio
Premium
7 November 2019
Worldwide sales at GlaxoSmithKline's (GSK's) Consumer Healthcare business increased by 25% at constant exchange rates in the third quarter of 2019, following consolidation of Pfizer’s Consumer Healthcare products.
People in brief | Microsoft, Bayer, Menarini, CRN
24 September 2019
GlaxoSmithKline's chief executive officer Emma Walmsley is set to join the board of Microsoft, while Bayer, Menarini and the US Council for Responsible Nutrition (CRN) have announced people changes.
FDA advisers back GSK's OTC nicotine oral spray
Premium
23 September 2019
Advisers to the US Food and Drug Administration (FDA) have recommended that GlaxoSmithKline (GSK) Consumer Healthcare's nicotine oral spray can be marketed as an OTC product.
Perrigo to acquire US OTC rights to Prevacid
Premium
9 September 2019
Perrigo is acquiring the US OTC rights to Prevacid 24HR (lansoprazole) from GlaxoSmithKline for an undisclosed sum. The company said the deal advanced its "Consumer Self-Care growth strategy".
GSK seeks OTC status for nicotine oral spray in US
Premium
20 August 2019
GlaxoSmithKline (GSK) Consumer Healthcare is seeking to extend its range of OTC nicotine-replacement therapy (NRT) products in the US with a nicotine oral spray.
GSK and Pfizer complete their joint venture
1 August 2019
GlaxoSmithKline (GSK) and Pfizer have now completed the deal to combine their consumer healthcare businesses into a world-leading joint venture.
Powerbrands drive GSK Consumer Healthcare
Premium
26 July 2019
Worldwide sales at GlaxoSmithKline's (GSK's) Consumer Healthcare business increased by 4% at constant exchange rates in the second quarter of 2019. The company said growth had been driven primarily by the performance of its powerbrands, including Sensodyne with sales growth of 7%.
GSK and Pfizer to divest ThermaCare brand
Premium
15 July 2019
The European Commission has given the go-ahead to GlaxoSmithKline's (GSK's) proposed consumer healthcare joint venture with Pfizer, provided the ThermaCare pain-management brand is divested.
GSK offers concessions and starts divestments
Premium
25 June 2019
GlaxoSmithKline (GSK) appears to have offered concessions to the European Commission as it seeks approval for its proposed consumer healthcare joint venture with Pfizer. Meanwhile, media reports suggest GSK has started a sale process for three portfolios of consumer healthcare products with a combin...